The troubles of Perjeta drug Essay Example

  • Category:
  • Document type:
  • Level:
  • Page:
  • Words:

Negative Health Effects of PERJETA Drug


The paper first introduces the mechanism of action of PERJETA drug and further explain the various negative health effects of the drug. It is a compiled report from various scientist and experts in the field of cancer.

PERJETA drug a tradenamefor Pertuzumab is a monoclonal antibody primarily used in breast cancer therapy. Thedrugworks by chunksthe dimerization of the extracellular human epidermal growth factor receptor 2 protein (HER2) together with other family members of HER, which include HERI, HER3, and HER4. Its impact is apoptosis and cell growth arrest as a result of ligand-initiated intracellular signaling inhibition. Pertuzumab instead arbitrates the Antibody-dependent cell-mediated cytotoxicity (Hoffman-La Roche Limited 2013). Pertuzumab alsostops homodimerization of HER2. Other effects include phosphoinositide 3 (PI3) kinase, mitogen-activated protein (MAP) kinase inhibition (Baselga et al. 2012).

Serious side effects occur when the drug extend their effects on normalcells near thetumorcells targeted during therapies (Gianni et al. 2012).The drug distribution, metabolism, andexcretion is not all information known. Forexample, theability of the drug crossing the brainbarrier is not available.

PERJETA has beencertified to be used in the combination with docetaxel and Herceptin, which shows better results than when used alone. Unfortunately, some patient show side effects although the withdrawal of docetaxel reduce the effects by 10% (Gianni et al. 2012). Commonly, the effects of PERJETA drug are hair loss, diarrhea, and fall of white blood cell in the blood despite the absence of fever.

The administration method of the drug must be done carefully by experts. Reports have been previously collected on decreased left ventricular ejection fraction (LVEF). High risks are noted for prior chest radio therapy and anthracyclines patients
(Hoffman-La Roche Limited 2013).Also from the collected reports, hypersensitivity reactions and infusion has been reported. This implies that not all patients can handle the effects of the mechanism of action of thedrug (Hoffman-La Roche Limited 2013). Therefore, the drug cannot be used by patients with pertuzumab allergy. Vomiting, asthenia, fatigue, fever, hypersensitivity, head-ache and fever are some of the infusion reactions. Also difficult breathing, face swelling, mouth ulcers, nausea, and constipation are reported (Baselga et al. 2012).

Heartfailuresymptoms that may includearmsandlegsswelling, cough, and breathing problemwhilesleepingflat are associated with PERJETA drugs (Baselga et al. 2012). Besides, theheart is unable to pumpblood at the optimal rate that causesrelatedsymptoms.

The monoclonal antibody limits some populations such as, Asian patients whose danger of febrile neutropenia is higher by 12% than the universal community if pertuzumab is accompanied with chemotherapy (Hoffman-La Roche Limited 2013).

With pregnant women, the study from animal studies indicates a definite risk of human fetal. The adverse renal histopathological transformation was exposing the role of HER2 in kidney development. Resultssuch as embryo-fetal death, kidney development delay of the fetus, and oligohydramnios were noted categorized as embryo-fetal toxicities. This limits the pregnant mothers from treatment that extends to potential parents (Hoffman-La Roche Limited 2013). Aperiod of seven-month birth control, therefore, applies since it takes up to 6 months to eliminate the PERJETA from thebody. Also, breast-feeding mothers fall in the category due to the latent secretion into breast milk.

Other very common side effects include dizziness, taste loss, more tears production, less appetite, nail problem, rash skin, and chest, neck, bone, and abdominal pains. Also, stomatitis decreased erythrocytes and lack of sleep.

Despite the outlined adverse health effects of PERJETA drugs, it has been proved to work effectively in for patients with metastatic HER2 and have not used any other anti-HER2 chemotherapy or therapy. It has a unique way of fighting cancer through different mechanisms

References Baselga, J., Cortés, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., … & Swain, S. M. (2012).
Pertuzumab plus trastuzumab plus docetaxel for metastatic breastcancer. Gianni, L., Pienkowski, T., Im, Y. H., Roman, L., Tseng, L. M., Liu, M. C., &Valagussa, P. (2012).
New England Journal of Medicine, 366(2), 109-119.Efficacyandsafety of neoadjuvant pertuzumab and trastuzumab in women with locallyadvanced, inflammatory, orearly HER2-positive breastcancer (NeoSphere): a randomized multicentre, open-label, phase 2 trial. Thelancet oncology, 13(1), 25-32.

Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; 12 April 2013.